



Bicillin® C-R (penicillin G benzathine/penicillin G procaine) products – Drug Shortage

- The [drug shortages](#) of Pfizer’s [Bicillin C-R \(penicillin G benzathine/penicillin G procaine\)](#) and [Bicillin C-R 900/300 \(penicillin G benzathine/penicillin G procaine\)](#) injections are ongoing. Bicillin C-R products have been unavailable for at least 90 days due to manufacturing delays.
- Bicillin C-R products are anticipated to be available during the 1st quarter of 2017.
- Bicillin C-R and Bicillin C-R 900/300 are indicated for the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form.
- Bicillin C-R and Bicillin C-R 900/300 are indicated in the treatment of the following in adults and pediatric patients:
 - Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci.
 - Moderately severe pneumonia and otitis media due to susceptible *Streptococcus pneumoniae*.

Product Description	Strength/Formulation	NDC #
Bicillin C-R (penicillin G benzathine/penicillin G procaine)	1.2 mU/2 mL injection	60793-0600-10; 60793-0601-10
Bicillin C-R 900/300 (penicillin G benzathine/penicillin G procaine)	1.2 mU/2 mL injection	60793-0602-10



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.